Obesity drug developer Metsera and kidney disease biotech Maze Therapeutics priced their Nasdaq IPOs on Thursday evening.
Metsera {$MTSR} will raise $275 million and Maze {$MAZE} will raise $140 million in their initial public offerings ...
↧
